Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Too Many Avoidable Suicides Occur Worldwide in Young Patients.

Rose K, Neubauer D, Grant-Kels JM.

Rambam Maimonides Med J. 2019 Oct 29;10(4). doi: 10.5041/RMMJ.10374. Review.

2.

The Challenges of Pediatric Drug Development.

Rose K.

Curr Ther Res Clin Exp. 2019 Jan 26;90:128-134. doi: 10.1016/j.curtheres.2019.01.007. eCollection 2019. Review.

3.

Are Regulatory Age Limits in Pediatric Melanoma Justified?

Rose K, Walson PD.

Curr Ther Res Clin Exp. 2019 Jan 18;90:113-118. doi: 10.1016/j.curtheres.2019.01.003. eCollection 2019. No abstract available.

4.

Questionable Industry-Sponsored Postneonatal Pediatric Studies in Slovenia.

Rose K, Neubauer D, Grant-Kels JM.

Curr Ther Res Clin Exp. 2019 Jan 18;90:86-91. doi: 10.1016/j.curtheres.2019.01.002. eCollection 2019.

5.

Rational Use of Medicine in Children-The Conflict of Interests Story. A Review.

Rose K, Neubauer D, Grant-Kels JM.

Rambam Maimonides Med J. 2019 Jul 18;10(3). doi: 10.5041/RMMJ.10371. Review.

6.

Pediatric melanoma-The whole (conflicts of interest) story.

Rose K, Grant-Kels JM.

Int J Womens Dermatol. 2018 Nov 19;5(2):110-115. doi: 10.1016/j.ijwd.2018.10.020. eCollection 2019 Jun. Review. No abstract available.

7.

The Meanings of "Pediatric Drug Development".

Rose K, Grant-Kels JM.

Ther Innov Regul Sci. 2019 Nov;53(6):767-774. doi: 10.1177/2168479018812060. Epub 2018 Dec 9.

PMID:
30526039
8.

Pediatric Melanoma and Drug Development.

Rose K, Grant-Kels JM.

Children (Basel). 2018 Mar 20;5(3). pii: E43. doi: 10.3390/children5030043.

9.

Most adolescents' melanomas are conventional malignant adult-type melanomas.

Rose K, Grant-Kels JM.

Eur J Cancer. 2018 May;95:117-119. doi: 10.1016/j.ejca.2018.01.080. Epub 2018 Feb 20. No abstract available.

PMID:
29475773
10.

Current state and future of pediatric allergology in Europe: A road map.

Tsilochristou O, Maggina P, Zolkipli Z, Sanchez Garcia S, Uysal P, Alvaro Lozano M, Atanaskovic-Markovic M, Baghdasaryan A, Beyer K, DuToit G, Gerth van Wijk R, Høst A, O'Hourihane J, Ingemann L, Kivistö JE, Lopes Dos Santos JM, Melén E, Muraro A, Nieto A, Pajno G, Rose K, Réthy LA, Sackesen C, Schmid Grendelmeier P, Valovirta E, Wickman M, Eigenmann PA, Wahn U, van der Poel LA.

Pediatr Allergy Immunol. 2018 Feb;29(1):9-17. doi: 10.1111/pai.12833.

PMID:
29168232
11.

Do Paediatric Investigation Plans (PIPs) Advance Paediatric Healthcare?

Rose K, Walson PD.

Paediatr Drugs. 2017 Dec;19(6):515-522. doi: 10.1007/s40272-017-0260-2.

PMID:
28889403
12.

The Effect of Regulation on Pediatric Psoriasis Drug Approvals: The Challenge of the European Union Pediatric Investigation Plans.

Rose K, Happle R.

Pediatr Dermatol. 2017 May;34(3):e154-e159. doi: 10.1111/pde.13097. No abstract available.

PMID:
28523878
13.

New Drugs for Rare Diseases in Children.

Rose K.

Clin Ther. 2017 Feb;39(2):246-252. doi: 10.1016/j.clinthera.2017.01.012. Epub 2017 Feb 1.

PMID:
28161117
14.

Do the European Medicines Agency Decisions Hurt Pediatric Melanoma Patients?

Rose K, Walson PD.

Clin Ther. 2017 Feb;39(2):253-265. doi: 10.1016/j.clinthera.2017.01.009. Epub 2017 Jan 31. Review.

PMID:
28159363
15.

Children with multiple sclerosis should not become therapeutic hostages.

Rose K, Müller T.

Ther Adv Neurol Disord. 2016 Sep;9(5):389-95. doi: 10.1177/1756285616656592. Epub 2016 Jul 11. Review.

16.

The contributions of the European Medicines Agency and its pediatric committee to the fight against childhood leukemia.

Rose K, Walson PD.

Risk Manag Healthc Policy. 2015 Nov 5;8:185-205. doi: 10.2147/RMHP.S63029. eCollection 2015. Review.

17.

Pediatric investigation plans for specific immunotherapy: Questionable contributions to childhood health.

Rose K, Kopp MV.

Pediatr Allergy Immunol. 2015 Dec;26(8):695-701. doi: 10.1111/pai.12500.

PMID:
26495999
18.

A New Ethical Challenge for Institutional Review Boards (IRBs)/Ethics Committees (ECs) in the Assessment of Pediatric Clinical Trials.

Rose K, Kummer H.

Children (Basel). 2015 May 28;2(2):198-210. doi: 10.3390/children2020198. Review.

19.
20.

Drug development: EU paediatric legislation, the European Medicines Agency and its Paediatric Committee--adolescents' melanoma as a paradigm.

Rose K, Senn S.

Pharm Stat. 2014 Jul-Aug;13(4):211-3. doi: 10.1002/pst.1623. Epub 2014 Jun 6.

PMID:
24903307

Supplemental Content

Loading ...
Support Center